VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q61170472  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000335.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q61170472‏
024 ‎‡a  0000-0002-9181-8902‏ ‎‡2  orcid‏
024 ‎‡a  57200387645‏ ‎‡2  scopus‏
024 ‎‡a  57203774990‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q61170472‏
100 0 ‎‡a  Daniel Berg‏ ‎‡c  researcher ORCID ID = 0000-0002-9181-8902‏ ‎‡9  en‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Daniel Berg‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's 5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice.‏
670 ‎‡a  Author's A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.‏
670 ‎‡a  Author's Activation of umbilical cord endothelial cells and fetal inflammatory response in preterm infants with chorioamnionitis and funisitis‏
670 ‎‡a  Author's Association of histologic chorioamnionitis, increased levels of cord blood cytokines, and intracerebral hemorrhage in preterm neonates‏
670 ‎‡a  Author's Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells.‏
670 ‎‡a  Author's CD4+ T cells from IL-10-deficient mice transfer susceptibility to NSAID-induced Rag colitis.‏
670 ‎‡a  Author's Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials.‏
670 ‎‡a  Author's Corrigendum to: Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells [Redox Biol. (2018) 82-87]‏
670 ‎‡a  Author's CpG DNA induces cyclooxygenase-2 expression and prostaglandin production.‏
670 ‎‡a  Author's Darier's disease: current understanding of pathogenesis and future role of genetic studies.‏
670 ‎‡a  Author's Decreased expression of angiogenic factors in placentas with chorioamnionitis after preterm birth.‏
670 ‎‡a  Author's Depletion of neutrophils in IL-10‏
670 ‎‡a  Author's Depletion of neutrophils in IL-10(-/-) mice delays clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter‏
670 ‎‡a  Author's Evidence for oxidative stress in NSAID-induced colitis in IL10-/- mice.‏
670 ‎‡a  Author's Il-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production.‏
670 ‎‡a  Author's Interleukin 10: An overview‏
670 ‎‡a  Author's Interleukin-10 gene knock-out mice: a model of chronic inflammation.‏
670 ‎‡a  Author's Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance.‏
670 ‎‡a  Author's O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.‏
670 ‎‡a  Author's Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.‏
670 ‎‡a  Author's Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer‏
670 ‎‡a  Author's Pharmacological Ascorbate as an Adjuvant for Enhancing Radiation-Chemotherapy Responses in Gastric Adenocarcinoma‏
670 ‎‡a  Author's Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.‏
670 ‎‡a  Author's R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.‏
670 ‎‡a  Author's Rapid development of colitis in NSAID-treated IL-10-deficient mice.‏
670 ‎‡a  Author's T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice.‏
670 ‎‡a  Author's The impact of educational loan burden on housestaff career decisions‏
670 ‎‡a  Author's Treatment of a pediatric patient with MET-amplified signet ring cell adenocarcinoma of the stomach with crizotinib‏
909 ‎‡a  (scopus) 57203774990‏ ‎‡9  1‏
909 ‎‡a  (scopus) 57200387645‏ ‎‡9  1‏
909 ‎‡a  (orcid) 0000000291818902‏ ‎‡9  1‏
919 ‎‡a  pharmacologicalascorbateasanadjuvantforenhancingradiationchemotherapyresponsesingastricadenocarcinoma‏ ‎‡A  Pharmacological Ascorbate as an Adjuvant for Enhancing Radiation-Chemotherapy Responses in Gastric Adenocarcinoma‏ ‎‡9  1‏
919 ‎‡a  consumingaketogenicdietwhilereceivingradiationandchemotherapyforlocallyadvancedlungcancerandpancreaticcancertheuniversityofiowaexperienceof2phase1clinicaltrials‏ ‎‡A  Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials.‏ ‎‡9  1‏
919 ‎‡a  associationofhistologicchorioamnionitisincreasedlevelsofcordbloodcytokinesandintracerebralhemorrhageinpretermneonates‏ ‎‡A  Association of histologic chorioamnionitis, increased levels of cord blood cytokines, and intracerebral hemorrhage in preterm neonates‏ ‎‡9  1‏
919 ‎‡a  phase2studyofmilataxelanoveltaxaneanalogueinpreviouslytreatedpatientswithadvancedcolorectalcancer‏ ‎‡A  A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.‏ ‎‡9  1‏
919 ‎‡a  interleukin10geneknockoutmiceamodelofchronicinflammation‏ ‎‡A  Interleukin-10 gene knock-out mice: a model of chronic inflammation.‏ ‎‡9  1‏
919 ‎‡a  interleukin10isacentralregulatoroftheresponsetolpsinmurinemodelsofendotoxicshockandtheshwartzmanreactionbutnotendotoxintolerance‏ ‎‡A  Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance.‏ ‎‡9  1‏
919 ‎‡a  pharmacokineticanalysisofirinotecanplusbevacizumabinpatientswithadvancedsolidtumors‏ ‎‡A  Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.‏ ‎‡9  1‏
919 ‎‡a  thelpercell1typecd4+tcellsbutnotbcellsmediatecolitisininterleukin10deficientmice‏ ‎‡A  T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice.‏ ‎‡9  1‏
919 ‎‡a  10isacentralregulatorofcyclooxygenase2expressionandprostaglandinproduction‏ ‎‡A  Il-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production.‏ ‎‡9  1‏
919 ‎‡a  depletionofneutrophilsinil10micedelaysclearanceofgastrichelicobacterinfectionanddecreasestheth1immuneresponsetohelicobacter‏ ‎‡A  Depletion of neutrophils in IL-10(-/-) mice delays clearance of gastric Helicobacter infection and decreases the Th1 immune response to Helicobacter‏ ‎‡9  1‏
919 ‎‡a  cd4+tcellsfromil10deficientmicetransfersusceptibilitytonsaidinducedragcolitis‏ ‎‡A  CD4+ T cells from IL-10-deficient mice transfer susceptibility to NSAID-induced Rag colitis.‏ ‎‡9  1‏
919 ‎‡a  augmentationofintracellularironusingironsucroseenhancesthetoxicityofpharmacologicalascorbateincoloncancercells‏ ‎‡A  Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells.‏ ‎‡9  1‏
919 ‎‡a  activationofumbilicalcordendothelialcellsandfetalinflammatoryresponseinpreterminfantswithchorioamnionitisandfunisitis‏ ‎‡A  Activation of umbilical cord endothelial cells and fetal inflammatory response in preterm infants with chorioamnionitis and funisitis‏ ‎‡9  1‏
919 ‎‡a  o2andh2o2mediateddisruptionoffemetabolismcausesthedifferentialsusceptibilityofnsclcandgbmcancercellstopharmacologicalascorbate‏ ‎‡A  O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate.‏ ‎‡9  1‏
919 ‎‡a  evidenceforoxidativestressinnsaidinducedcolitisinil10mice‏ ‎‡A  Evidence for oxidative stress in NSAID-induced colitis in IL10-/- mice.‏ ‎‡9  1‏
919 ‎‡a  pharmacologicalascorbatewithgemcitabineforthecontrolofmetastaticandnodepositivepancreaticcancerpacmanresultsfromaphase1clinicaltrial‏ ‎‡A  Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.‏ ‎‡9  1‏
919 ‎‡a  rspondin1anovelintestinotrophicmitogenamelioratesexperimentalcolitisinmice‏ ‎‡A  R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.‏ ‎‡9  1‏
919 ‎‡a  pharmacologicascorbatereducesradiationinducednormaltissuetoxicityandenhancestumorradiosensitizationinpancreaticcancer‏ ‎‡A  Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer‏ ‎‡9  1‏
919 ‎‡a  treatmentofapediatricpatientwithmetamplifiedsignetringcelladenocarcinomaofthestomachwithcrizotinib‏ ‎‡A  Treatment of a pediatric patient with MET-amplified signet ring cell adenocarcinoma of the stomach with crizotinib‏ ‎‡9  1‏
919 ‎‡a  cpgdnainducescyclooxygenase2expressionandprostaglandinproduction‏ ‎‡A  CpG DNA induces cyclooxygenase-2 expression and prostaglandin production.‏ ‎‡9  1‏
919 ‎‡a  rapiddevelopmentofcolitisinnsaidtreatedil10deficientmice‏ ‎‡A  Rapid development of colitis in NSAID-treated IL-10-deficient mice.‏ ‎‡9  1‏
919 ‎‡a  5lipoxygenasederivedlipidmediatorsarenotrequiredforthedevelopmentofnsaidinducedinflammatoryboweldiseaseinil10mice‏ ‎‡A  5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice.‏ ‎‡9  1‏
919 ‎‡a  depletionofneutrophilsinil10‏ ‎‡A  Depletion of neutrophils in IL-10‏ ‎‡9  1‏
919 ‎‡a  decreasedexpressionofangiogenicfactorsinplacentaswithchorioamnionitisafterpretermbirth‏ ‎‡A  Decreased expression of angiogenic factors in placentas with chorioamnionitis after preterm birth.‏ ‎‡9  1‏
919 ‎‡a  corrigendumtoaugmentationofintracellularironusingironsucroseenhancesthetoxicityofpharmacologicalascorbateincoloncancercells‏ ‎‡A  Corrigendum to: Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells [Redox Biol. (2018) 82-87]‏ ‎‡9  1‏
919 ‎‡a  dariersdiseasecurrentunderstandingofpathogenesisandfutureroleofgeneticstudies‏ ‎‡A  Darier's disease: current understanding of pathogenesis and future role of genetic studies.‏ ‎‡9  1‏
919 ‎‡a  impactofeducationalloanburdenonhousestaffcareerdecisions‏ ‎‡A  The impact of educational loan burden on housestaff career decisions‏ ‎‡9  1‏
919 ‎‡a  interleukin10anoverview‏ ‎‡A  Interleukin 10: An overview‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  BIBSYS|3065820‏
996 ‎‡2  LC|n 2007007441‏
996 ‎‡2  ISNI|0000000042138180‏
996 ‎‡2  BNF|16267865‏
996 ‎‡2  ISNI|0000000402475704‏
996 ‎‡2  ISNI|0000000396204915‏
996 ‎‡2  DNB|114898936‏
996 ‎‡2  LIH|LNB:B10H;=_h_I‏
996 ‎‡2  NTA|364186895‏
996 ‎‡2  W2Z|12047884‏
996 ‎‡2  RERO|A000018513‏
996 ‎‡2  LC|n 84135042‏
996 ‎‡2  BIBSYS|90189219‏
996 ‎‡2  NTA|33164830X‏
996 ‎‡2  ISNI|000000007640765X‏
996 ‎‡2  JPG|500748226‏
996 ‎‡2  BIBSYS|11074229‏
996 ‎‡2  DNB|1228168210‏
996 ‎‡2  ISNI|0000000042208599‏
996 ‎‡2  NUKAT|n 2015007570‏
996 ‎‡2  DNB|118509349‏
996 ‎‡2  LC|no2016143477‏
996 ‎‡2  NLR|RU NLR AUTH 77106821‏
996 ‎‡2  ISNI|0000000079103918‏
996 ‎‡2  LC|n 78034117‏
996 ‎‡2  NDL|00432985‏
996 ‎‡2  BIBSYS|90651926‏
996 ‎‡2  ISNI|0000000394357387‏
996 ‎‡2  NUKAT|n 2003091854‏
996 ‎‡2  CAOONL|ncf10241327‏
996 ‎‡2  NDL|01225097‏
996 ‎‡2  ISNI|000000042759518X‏
996 ‎‡2  ISNI|0000000016791864‏
996 ‎‡2  LC|no2002084882‏
996 ‎‡2  ISNI|0000000118875284‏
996 ‎‡2  NSK|000302243‏
996 ‎‡2  RERO|A002992958‏
996 ‎‡2  ISNI|000000041609577X‏
996 ‎‡2  RERO|A009148923‏
996 ‎‡2  ISNI|0000000032770297‏
996 ‎‡2  LC|n 98107318‏
996 ‎‡2  ISNI|000000044383577X‏
996 ‎‡2  ISNI|0000000456608832‏
996 ‎‡2  NII|DA0187444X‏
996 ‎‡2  SUDOC|080637051‏
996 ‎‡2  LC|n 82247805‏
996 ‎‡2  CAOONL|ncf12105604‏
996 ‎‡2  W2Z|10008663‏
996 ‎‡2  DBC|87097968257018‏
996 ‎‡2  NII|DA10245117‏
996 ‎‡2  W2Z|13037613‏
996 ‎‡2  SELIBR|304680‏
996 ‎‡2  SUDOC|195001222‏
996 ‎‡2  NTA|262262193‏
996 ‎‡2  LC|nb2002080610‏
996 ‎‡2  DNB|12603771X‏
996 ‎‡2  NTA|074674536‏
996 ‎‡2  DNB|1191947130‏
996 ‎‡2  ISNI|0000000048781556‏
996 ‎‡2  BIBSYS|5013279‏
996 ‎‡2  ISNI|000000007596207X‏
996 ‎‡2  ISNI|0000000046749931‏
996 ‎‡2  NUKAT|n 2017169728‏
996 ‎‡2  J9U|987007966587405171‏
996 ‎‡2  SELIBR|304677‏
996 ‎‡2  SELIBR|304676‏
996 ‎‡2  ISNI|0000000080165032‏
996 ‎‡2  LC|no 92024888‏
996 ‎‡2  DNB|1176984969‏
996 ‎‡2  NTA|292017782‏
996 ‎‡2  LC|n 86135047‏
996 ‎‡2  RERO|A016439112‏
996 ‎‡2  J9U|987007269423505171‏
996 ‎‡2  SUDOC|189307625‏
996 ‎‡2  SELIBR|356132‏
996 ‎‡2  ISNI|0000000051612016‏
996 ‎‡2  W2Z|8031148‏
996 ‎‡2  DNB|123756863‏
996 ‎‡2  J9U|987007319672405171‏
996 ‎‡2  NUKAT|n 2013124388‏
996 ‎‡2  NII|DA17175348‏
996 ‎‡2  LC|no2006050667‏
996 ‎‡2  DNB|128491221‏
996 ‎‡2  BNF|16662629‏
996 ‎‡2  DNB|143644629‏
996 ‎‡2  LC|n 77016529‏
996 ‎‡2  LC|n 2024032566‏
996 ‎‡2  ISNI|000000035311889X‏
996 ‎‡2  J9U|987007258528005171‏
996 ‎‡2  ISNI|0000000039629931‏
996 ‎‡2  LC|no2019174472‏
996 ‎‡2  ISNI|0000000032977423‏
996 ‎‡2  NLA|000035560505‏
996 ‎‡2  ISNI|0000000382865616‏
996 ‎‡2  J9U|987007431080305171‏
996 ‎‡2  ISNI|0000000078562143‏
996 ‎‡2  J9U|987007357630605171‏
996 ‎‡2  LC|n 2020025681‏
996 ‎‡2  ICCU|LO1V377696‏
996 ‎‡2  DNB|1062144139‏
996 ‎‡2  ISNI|0000000497736048‏
996 ‎‡2  LC|no2017094302‏
996 ‎‡2  LC|n 2003102177‏
996 ‎‡2  DNB|134245832X‏
996 ‎‡2  LC|n 89648169‏
996 ‎‡2  SELIBR|398780‏
996 ‎‡2  LC|n 2018187212‏
996 ‎‡2  LC|no 97051100‏
996 ‎‡2  ISNI|0000000393163775‏
996 ‎‡2  NUKAT|n 2008121289‏
996 ‎‡2  CAOONL|ncf10382397‏
996 ‎‡2  W2Z|3065820‏
996 ‎‡2  NTA|398187304‏
996 ‎‡2  ISNI|000000039492074X‏
996 ‎‡2  SUDOC|17861565X‏
996 ‎‡2  ISNI|0000000030347401‏
996 ‎‡2  DNB|1278491090‏
996 ‎‡2  PLWABN|9810533569905606‏
996 ‎‡2  DBC|870979134594632‏
996 ‎‡2  J9U|987007425835605171‏
996 ‎‡2  BIBSYS|13037613‏
996 ‎‡2  SELIBR|341435‏
996 ‎‡2  NTA|437893669‏
996 ‎‡2  ISNI|000000004582715X‏
996 ‎‡2  PLWABN|9810641556205606‏
996 ‎‡2  DNB|127834710‏
996 ‎‡2  LC|n 85155903‏
996 ‎‡2  J9U|987007587210205171‏
996 ‎‡2  BNF|13788135‏
996 ‎‡2  NTA|156846640‏
996 ‎‡2  NTA|377325635‏
996 ‎‡2  LC|nb 99026655‏
996 ‎‡2  NTA|166517763‏
996 ‎‡2  CAOONL|ncf10384343‏
996 ‎‡2  NTA|151766452‏
996 ‎‡2  SELIBR|dtzjsjf7bq9pvsqc‏
996 ‎‡2  DNB|1135294879‏
996 ‎‡2  DNB|122837568‏
996 ‎‡2  PLWABN|9810700605405606‏
996 ‎‡2  NTA|240701739‏
996 ‎‡2  BIBSYS|8031148‏
996 ‎‡2  ISNI|0000000389889418‏
996 ‎‡2  DNB|1037513193‏
996 ‎‡2  ISNI|0000000033690512‏
996 ‎‡2  LC|n 97078232‏
996 ‎‡2  NLR|RU NLR AUTH 77106816‏
996 ‎‡2  SUDOC|150902972‏
996 ‎‡2  BIBSYS|90155290‏
996 ‎‡2  J9U|987007437332905171‏
996 ‎‡2  RERO|A018534963‏
996 ‎‡2  ISNI|0000000498480355‏
996 ‎‡2  CAOONL|ncf11010653‏
996 ‎‡2  NTA|146225414‏
996 ‎‡2  DBC|87097968118298‏
996 ‎‡2  NSK|000334916‏
996 ‎‡2  ISNI|000000003386253X‏
996 ‎‡2  ISNI|0000000399296077‏
996 ‎‡2  ISNI|0000000025430630‏
996 ‎‡2  ISNI|0000000395064113‏
996 ‎‡2  LC|n 82237092‏
996 ‎‡2  BNF|16743022‏
996 ‎‡2  NTA|100654053‏
996 ‎‡2  LC|n 2012077653‏
996 ‎‡2  LC|n 90649658‏
996 ‎‡2  NUKAT|n 2013137995‏
996 ‎‡2  ISNI|0000000024779857‏
996 ‎‡2  NTA|369211677‏
996 ‎‡2  ISNI|0000000031905882‏
996 ‎‡2  J9U|987007445814205171‏
996 ‎‡2  PLWABN|9810573529105606‏
996 ‎‡2  LC|no2010204115‏
996 ‎‡2  ISNI|0000000041120341‏
996 ‎‡2  DNB|1217854479‏
996 ‎‡2  RERO|A017243272‏
996 ‎‡2  BIBSYS|2059163‏
996 ‎‡2  LC|no2006102389‏
996 ‎‡2  NTA|072472855‏
996 ‎‡2  LC|n 85240514‏
996 ‎‡2  ISNI|000000038757317X‏
996 ‎‡2  CAOONL|ncf11924173‏
996 ‎‡2  ISNI|0000000028171259‏
996 ‎‡2  ISNI|0000000051961208‏
996 ‎‡2  ISNI|0000000012528794‏
996 ‎‡2  NUKAT|n 2009120754‏
996 ‎‡2  BIBSYS|98014863‏
996 ‎‡2  LC|no 96011206‏
996 ‎‡2  DNB|1204936218‏
996 ‎‡2  ISNI|0000000110034819‏
996 ‎‡2  J9U|987012616151205171‏
996 ‎‡2  SUDOC|129535192‏
996 ‎‡2  BNC|981058529993606706‏
996 ‎‡2  LC|n 2017005231‏
996 ‎‡2  ISNI|0000000390536150‏
996 ‎‡2  NUKAT|n 2012076044‏
996 ‎‡2  LC|n 87810524‏
996 ‎‡2  LC|n 85269992‏
996 ‎‡2  DNB|135602610‏
996 ‎‡2  CAOONL|ncf11613659‏
996 ‎‡2  PLWABN|9810648632405606‏
996 ‎‡2  BIBSYS|90245876‏
996 ‎‡2  RERO|A002992959‏
996 ‎‡2  ISNI|0000000021622213‏
996 ‎‡2  BLBNB|000218866‏
996 ‎‡2  CAOONL|ncf11558355‏
996 ‎‡2  DNB|128526211‏
996 ‎‡2  LC|no2023109538‏
996 ‎‡2  LC|no 95035773‏
996 ‎‡2  PLWABN|9810653925205606‏
996 ‎‡2  BIBSYS|10008663‏
996 ‎‡2  DNB|108444147‏
996 ‎‡2  RERO|A002992956‏
996 ‎‡2  SUDOC|189369051‏
996 ‎‡2  ISNI|0000000391941465‏
996 ‎‡2  BIBSYS|12047884‏
996 ‎‡2  CAOONL|ncf11866121‏
996 ‎‡2  ISNI|0000000116444077‏
996 ‎‡2  LC|no2015129875‏
996 ‎‡2  NTA|321355741‏
996 ‎‡2  LC|n 96064444‏
996 ‎‡2  LC|nb2011006790‏
996 ‎‡2  DNB|1154318141‏
996 ‎‡2  DNB|1207104809‏
996 ‎‡2  NDL|00558776‏
996 ‎‡2  LC|n 86811323‏
996 ‎‡2  BLBNB|000218867‏
996 ‎‡2  NTA|124254640‏
996 ‎‡2  DNB|1153443066‏
996 ‎‡2  JPG|500074264‏
996 ‎‡2  DNB|1301568953‏
996 ‎‡2  ISNI|0000000051774488‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏